Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurodegeneration
Biotech
Novartis ends ALS program after phase 2 flop, adding to R&D woes
Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial.
Nick Paul Taylor
Sep 16, 2026 10:28am
Novartis pens BioArctic neuro pact worth $30M upfront
Aug 26, 2025 8:30am
Lilly pays QurAlis $45M for preclinical ALS, dementia prospect
Jun 3, 2024 5:00am
AbbVie continues Parkinson's pursuit with $110M Mitokinin buy
Oct 5, 2023 10:30am
BMS pays $95M to exercise Evotec, Prothena neuroscience options
Jul 11, 2023 5:30am
Biogen trims Denali-partnered Parkinson's program in half
Jun 5, 2023 10:50am
